SEC Form 4 · accession 0000911916-16-000654
CoLucid Pharmaceuticals, Inc. · CLCD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Linda C. Hogan
Officer — Head, Bus. Dev. and Strategy
Period of report
Sep 6, 2016
Accepted (ET)
Sep 7, 2016 · 5:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348649
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 6, 2016 | M | 36,452 | $10.00 | A | 36,452 | D | |
| Common Stock | Sep 6, 2016 | M | 3,518 | $7.56 | A | 39,970 | D | |
| Common Stock | Sep 6, 2016 | M | 5,031 | $6.75 | A | 45,001 | D | |
| Common StockF1 | Sep 6, 2016 | S | 8,549 | $19.50 | D | 36,452 | D | |
| Common StockF1 | Sep 6, 2016 | S | 5,032 | $20.00 | D | 31,420 | D | |
| Common StockF1,F2 | Sep 6, 2016 | S | 31,420 | $20.0011 | D | 0 | D | |
| Common Stock | Sep 6, 2016 | M | 2,839 | $5.09 | A | 2,839 | I | By LLH Associates, LLC |
| Common Stock | Sep 6, 2016 | M | 896 | $5.09 | A | 3,735 | I | By LLH Associates, LLC |
| Common StockF1 | Sep 6, 2016 | S | 3,735 | $19.50 | D | 0 | I | By LLH Associates, LLC |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $10.00 | Sep 6, 2016 | M | 36,452 | D | — | May 5, 2025 | Common Stock | 36,452 | 53,675 | D |
| Stock Option (Right to Buy)F4 | $7.56 | Sep 6, 2016 | M | 3,518 | D | — | Aug 4, 2025 | Common Stock | 3,518 | 6,482 | D |
| Stock Option (Right to Buy)F5 | $6.75 | Sep 6, 2016 | M | 5,031 | D | — | Mar 4, 2026 | Common Stock | 5,031 | 29,469 | D |
| Stock Option (Right to Buy)F6 | $5.09 | Sep 6, 2016 | M | 2,839 | D | — | Oct 29, 2018 | Common Stock | 2,839 | 0 | I |
| Stock Option (Right to Buy)F6 | $5.09 | Sep 6, 2016 | M | 896 | D | — | Feb 2, 2019 | Common Stock | 896 | 0 | I |
Explanation of responses
- F1Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Ms. Hogan on March 24, 2016.
- F2Represents the sale of 31,420 shares in multiple transactions, ranging in price from $20.00 to $20.025 per share, resulting in a weighted average sale price of $20.0011. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- F3Options vest as follows: 33% of the shares vested on May 5, 2016; and the remaining shares vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.
- F4Options vest as follows: one-third of the shares vested on August 4, 2016; and the remaining shares vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.
- F5Options vest in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month.
- F6This option is fully vested.